A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9001 (Delandistrogene Moxeparvovec) in Participants With Duchenne Muscular Dystrophy (DMD)

  • Duchenne Muscular Dystrophy (DMD)
Trial Status:

Active, not recruiting

This trial runs in
  • United States
Trial Identifier:

NCT03375164 IRB17-00512 SRP-9001-101

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This is an open-label single-dose gene transfer therapy study evaluating the safety of SRP-9001 (delandistrogene moxeparvovec) intravenous (IV) administration in boys with DMD. This study will consist of 2 Cohorts. Cohort A will include participants ages 3 months to 3 years, and Cohort B will include participants ages 4 to 7 years old. All participants in the study will receive IV SRP-9001.

      Sarepta Therapeutics, Inc. Sponsor
      Phase 1/Phase 2 Phase
      NCT03375164 , SRP-9001-101 , IRB17-00512 Trial Identifier
      SRP-9001 Treatments
      Duchenne Muscular Dystrophy Condition
      Official Title

      Systemic Gene Delivery Phase I/IIa Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MHCK7.Micro-dystrophin (microDys-IV-001)

      Eligibility Criteria

      Male Gender
      ≥3 Months & ≤ 7 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Cohort A participants: 3 months to 3 years of age, inclusive
      • Cohort B participants: 4 to 7 years of age, inclusive
      • Definitive diagnosis of DMD based on documented clinical findings and prior genetic testing.
      • Ability to cooperate with motor assessment testing.
      • Cohort A participants: No previous treatment with corticosteroids.
      • Cohort B participants: Stable dose equivalent of oral corticosteroids for at least 12 weeks prior to screening and the dose is expected to remain constant (except for potential modifications to accommodate changes in weight) throughout the first year of the study.
      • Cohorts A & B: A frameshift mutation contained between exons 18 and 58 (inclusive).
      Exclusion Criteria
      • Exposure to gene therapy, investigational medication, or any treatment designed to increase dystrophin expression within protocol specified time limits.
      • Abnormality in protocol-specified diagnostic evaluations or laboratory tests.
      • Presence of any other clinically significant illness, medical condition, or requirement for chronic drug treatment that in the opinion of the Investigator creates unnecessary risk for gene transfer.

      Other inclusion or exclusion criteria could apply.

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now